Scientists have achieved a landmark breakthrough in neuroimaging with the development of [11C]MODAG-005, the first positron emission tomography tracer successfully capable of detecting alpha-synuclein protein aggregates in living brains. This achievement, published in Science Translational Medicine, represents a major milestone after decades of failed attempts to create a tracer with sufficient specificity and brain penetration.
The tracer demonstrates remarkable sensitivity, showing 2.8 times higher binding intensity in the substantia nigra of Parkinson’s patients compared to healthy controls, with significant elevation across other affected brain regions. Alpha-synuclein accumulation is the pathological hallmark of Parkinson’s disease and related synucleinopathies, conditions that affect millions globally.
This development promises to transform clinical practice by enabling visualization of disease pathology before neuronal damage becomes irreversible, potentially shifting diagnosis from a symptomatic assessment to a precision molecular approach.
Read the full article on GMJ Newsroom.
Was this article helpful?
